tbuckley/cabot-search huggingface dataset:
Deaths
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
We Are All the Same
Authors: Mandy L. Maneval
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What Is Multiple Myeloma?
Authors: Juliet Silberstein, Sascha Tuchman, Shakira J. Grant
Journal: JAMA (2022)

Andrew J. Cowan, MD; Damian J. Green, MD; Mary Kwok, MD; Sarah Lee, MD; David G. Coffey, MD; Leona A. Holmberg, MD, PhD; Sherilyn Tuazon, MD; Ajay K. Gopal, MD; Edward N. Libby, MD
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
Authors: Vibeke Strand, Gurjit S Kaeley, Martin J Bergman, Dafna D Gladman, Laura C Coates, Bintu Sherif, Peter Hur, Bhumik Parikh, Isabelle Gilloteau, Philip J Mease
Journal: The Lancet Rheumatology (2022)
<i>QuickStats</i>: Emergency Department Visit Rates* for Motor Vehicle Crashes,<sup>†</sup> by Age Group — United States, 2018<sup>§</sup>
Authors: Jill Ashman, ; Christopher
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Total ≤14 15-24 25-64 ≥65 Rate per 1,000 persons Age group (yrs) * Visit rates are based on the July 1, 2018, set of estimates of the U.S. civilian noninstitutionalized population as developed by the U.S. Census Bureau, Population Division.95% confidence intervals indicated with error bars.† Motor vehicle crashes defined as a visit with International Classification of Diseases, Tenth Revision, Clinical Modification codes: [V02-V04] (with fourth character = 1, 9), V09.2, V09.3, [V12-V14, V20-V28] (with fourth character = 3, 4, 5, 9), V19.4-V19.6,V19.9, V29.4-V29.9,[V30-V79] (with fourth character = 4, 5, 6, 7, 8, 9), [V83-V86] (with fourth character = 0, 1, 2, 3), V80.3-V80.5,V81.1, V82.1, V87.0-V87.8,V89.2, X81.0, X82, Y02.0, Y03, Y32.Injured persons included motor vehicle occupants, motorcyclists, pedal cyclists, and pedestrians.§ Based on a sample of visits to emergency departments in noninstitutional general and short-stay hospitals, exclusive of federal, military, and Veterans Administration hospitals, located in the 50 U.S. states and the District of Columbia.In 2018, the U.S. emergency department (ED) visit rate for motor vehicle crashes was 10.5 visits per 1,000 persons.The ED visit rate for motor vehicle crashes among persons aged 0-14 years was 7.1 ED visits per 1,000 persons.The visit rate for motor vehicle crashes was highest for persons aged 15-24 years (18.6) and declined with age to 11.7 for those aged 25-64 years and to 4.2 for those aged ≥65 years.
Agonistic CD40 Antibodies and Cancer Therapy
Authors: Robert H. Vonderheide, Martin J. Glennie
Journal: Clinical Cancer Research (2013)

Abstract Recent success in cancer immunotherapy has reinvigorated the hypothesis that the immune system can control many if not most cancers, in some cases producing durable responses in a way not seen with many small-molecule drugs. Agonistic CD40 monoclonal antibodies (mAb) offer a new therapeutic option which has the potential to generate anticancer immunity by various mechanisms. CD40 is a TNF receptor superfamily member expressed broadly on antigen-presenting cells (APC) such as dendritic cells, B cells, and monocytes as well as many nonimmune cells and a range of tumors. Agonistic CD40 mAb have been shown to activate APC and promote antitumor T-cell responses and to foster cytotoxic myeloid cells with the potential to control cancer in the absence of T-cell immunity. Thus, agonistic CD40 mAb are fundamentally different from mAb which block negative immune checkpoint such as anti-CTLA-4 or anti-PD-1. Initial clinical trials of agonistic CD40 mAb have shown highly promising results in the absence of disabling toxicity, both in single-agent studies and in combination with chemotherapy; however, numerous questions remain about dose, schedule, route of administration, and formulation. Recent findings about the role played by the IgG isotype and the Fc gamma receptor (FcγR) in mAb cross-linking, together with insights into mechanisms of action, particularly with regard to the role of myeloid cells, are predicted to help design next-generation CD40 agonistic reagents with greater efficacy. Here, we will review the preclinical and clinical data and discuss the major issues facing the field. Clin Cancer Res; 19(5); 1035–43. ©2013 AACR.
New Instrument.
Journal: JAMA (1903)

<h3>A COMBINED LINT CARRIER AND FLEXIBLE PROBE.</h3> RICHARD LIGHTBURN SUTTON, M.D. ASSISTANT SURGEON, UNITED STATES NAVY. WASHINGTON, D. C. Anyone who has tried the ordinary probes, directors and forceps for inserting gauze or lint drains into narrow passages or deep wounds is fully aware of the difficulty often encountered in the slight, but frequently tedious, performance. An instrument which is sufficiently stiff and unyielding to ensure a positive hold on the strip of drainage material is seldom flexible enough to allow of its being pushed through any except an almost direct passage, while the pliable ones now in use, so far as I have been able to find, have either a plain, rounded point, to which it is extremely difficult for one to attach a piece of gauze in such a manner as to insert it in a wound and have it remain there when the instrument is withdrawn, or
The Pathogenesis And Treatment Of Acne
Authors: P. Pochi
Journal: Annual Review of Medicine (1990)

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 ...Read More
Successfully Reducing Severe Asthma Exacerbations and Improving Asthma Control in a Pragmatic Study in African American/Black (AA/B) and Hispanic/Latinx (H/L) Patients with Moderate-Severe Asthma (PREPARE)
Authors: Juan Carlos Cardet, Wilson Pace, Jennifer Carroll, Anne Fuhlbrigge, Lilin She, Frank Rockhold, Nancy Maher, Maureen Fagan, Victoria Forth, Paulina Arias Hernandez, Jean Kruse, Brian Manning, Jacqueline Rodriguez-Louis, Joel Shields, Brianna Ericson, Alex Colon-Moya, Tamera Coyne-Beasley, Gretchen Hammer, Barbara Kaplan, Suzanne Madisson, Cynthia Rand, Janet Robles, Opal Thompson, Michael Wechsler, Juan Wisnivesky, Diane McKee, Sunit Jariwala, Elina Jerschow, Paula Busse, David Kaelber, Sylvette Nazario, Michelle Hernandez, Andrea Apter, Ku-Lang Chang, Victor Pinto-Plata, Paul Stranges, Laura Hurley, Jennifer Trevor, Thomas Casale, Geoffrey Chupp, Isaretta Riley, Kartik Shenoy, Magdalena Pasarica, Rafael Calderon-Candelario, Hazel Tapp, Ahmet Baydur, Barbara Yawn, Elliot Israel
Journal: Journal of Allergy and Clinical Immunology (2022)
Evaluation of Trends in Homeschooling Rates After Elimination of Nonmedical Exemptions to Childhood Immunizations in California, 2012-2020
Authors: Kavin M. Patel, SarahAnn M. McFadden, Salini Mohanty, Caroline M. Joyce, Paul L. Delamater, Nicola P. Klein, Daniel A. Salmon, Saad B. Omer, Alison M. Buttenheim
Journal: JAMA Network Open (2022)

In 2015, California passed Senate Bill No. 277 (SB 277) and became the first state in more than 30 years to eliminate nonmedical exemptions to mandatory childhood immunizations for school entry. One concern that emerged was that the law created an incentive for parents to remove children from brick-and-mortar schools to bypass the immunization requirements.
Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters
Authors: Michael Brada, Helen Forbes, Susan Ashley, John Fenwick
Journal: Journal of Thoracic Oncology (2022)

We analyzed a comprehensive national radiotherapy data set to compare outcomes of the most frequently used moderate hypofractionation regimen (55 Gy in 20 fractions) and conventional fractionation regimen (60-66 Gy in 30-33 fractions).
Lymphocyte-depletion Hodgkin's disease.
Journal: BMJ (1973)

therapy for several years.416J.H. Burchenal,17 from a world- wide survey of long-term survivors in acute leukaemia, found that 50% of those who had survived five years went on to survive 15 years, generally being off all chemotherapy for the latter part of this time, none relapsing after eight years of continuous remission.If this finding can be applied to more recent series, in which 40 to 50% of patients are expected to reach five years without recurrence, then 20 to 25% should reach 15 years, which would surely indicate cure.
Brefeldin a modifies the transcytotic vesicular transport of horseradish peroxidase (HRP) in isolated rat hepatocyte couplets and bile ductular cells A. Benedetti, L. Marucci, C. Bassotti, C. Guidarelli, G. Macarri, A. M. Jezequel, F. Orlandi. Department of Gastroenterology and Institute of Experimental Pathology, University of Ancona, School of Medicine, Ancona, Italy
Journal: Hepatology (1994)
Development of an Open Database of Genes Included in Hereditary Cancer Genetic Testing Panels Available From Major Sources in the US
Authors: Janis Geary, Mary Majumder, Christi Guerrini, Robert Cook-Deegan
Journal: JAMA Oncology (2022)

This quality improvement study describes the development of an open database of genes included in hereditary cancer genetic testing panels from major US providers and also discusses publicly available variant data for those genes.
The Etiology and Pathology of Typhus. The Main Report of the Typhus Research Commission of the League of Red Cross Societies to Poland.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bio-inspired, bio-degradable adenosine 5′-diphosphate-modified hyaluronic acid coordinated hydrophobic undecanal-modified chitosan for hemostasis and wound healing
Authors: Yihao Liu, Haoyi Niu, Chengwei Wang, Xiaoxiao Yang, Wentao Li, Yuxin Zhang, Xiaojun Ma, Yuanjing Xu, Pengfei Zheng, Jinwu Wang, Kerong Dai
Journal: Bioactive Materials (2022)

Uncontrolled hemorrhage and wound infection are crucial causes of trauma-associated death in both the military and the clinic. Therefore, developing an efficient and rapid hemostatic method with biocompatibility, easy degradation, and wound healing is of great importance and desirability. Inspired by spontaneous blood cell plug formation in the hemostasis process, an adenosine 5′-diphosphate modified pro-coagulation hyaluronic acid (HA-ADP) coordinated with enhanced antibacterial activity of undecanal-modified chitosan (UCS) was fabricated through physical electrostatic cross-linking and freeze-drying. The as-prepared hydrogel sponges showed a porous structure suitable for blood cell adhesion. In particular, the hydrogel exhibited excellent antibacterial ability and promoted the adhesion of platelets and red blood cells, thus inducing a prominent pro-coagulation ability via platelet activation, which exhibits a shorter hemostasis time (58.94% of control) in vitro. Compared with commercially available CELOX and gelatin sponge (GS), HA-ADP/UCS accelerates hemostasis and reduces blood loss in both rat tail amputation and rat artery injury models. Furthermore, all the samples exhibited superior cytocompatibility and biodegradability. Due to these performances, HA-ADP/UCS promoted full-thickness skin defect healing significantly in vivo. All the properties of HA-ADP/UCS suggest that it has great potential for translation as a clinical application material for hemostatic and wound healing.
Patient Use Of Non-Standard Terms For Asthma Inhalers Is Associated With Worse Asthma Morbidity Outcomes
Authors: Victoria Forth, Paulina Arias Hernandez, Jennifer Carroll, Brianna Ericson, Jing Cui, Maureen Fagan, Anne Fuhlbrigge, Laura Hurley, Jean Kruse, Nancy Maher, Brian Manning, Giselle Mosnaim, Wilson Pace, Wanda Phipatanakul, Jacqueline Rodriguez-Louis, Justin Salciccioli, Joel Shields, Elizabeth Staton, Bonnie Telon Sosa, Elliot Israel
Journal: Journal of Allergy and Clinical Immunology (2022)
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
Authors: M. Martello, A. Poletti, E. Borsi, V. Solli, L. Dozza, S. Barbato, E. Zamagni, P. Tacchetti, L. Pantani, K. Mancuso, I. Vigliotta, I. Rizzello, S. Rocchi, S. Armuzzi, N. Testoni, G. Marzocchi, G. Martinelli, M. Cavo, C. Terragna
Journal: Blood Cancer Journal (2022)

Abstract Aberrations on TP53 , either as deletions of chromosome 17p (del17p) or mutations, are associated with poor outcome in multiple myeloma (MM), but conventional detection methods currently in use underestimate their incidence, hindering an optimal risk assessment and prognostication of MM patients. We have investigated the altered status of TP53 gene by SNPs array and sequencing techniques in a homogenous cohort of 143 newly diagnosed MM patients, evaluated both at diagnosis and at first relapse: single-hit on TP53 gene, either deletion or mutation, detected both at clonal and sub-clonal level, had a minor effect on outcomes. Conversely, the coexistence of both TP53 deletion and mutation, which defined the so-called double-hit patients, was associated with the worst clinical outcome (PFS: HR 3.34 [95% CI: 1.37–8.12] p = 0.008; OS: HR 3.47 [95% CI: 1.18–10.24] p = 0.02). Moreover, the analysis of longitudinal samples pointed out that TP53 allelic status might increase during the disease course. Notably, the acquisition of TP53 alterations at relapse dramatically worsened the clinical course of patients. Overall, our analyses showed these techniques to be highly sensitive to identify TP53 aberrations at sub-clonal level, emphasizing the poor prognosis associated with double-hit MM patients.
Differential induction of trained innate immunity following early-life immunization with aluminum adjuvant results in preferential priming of Th2-biased immune responses
Authors: Olivia Benson, Jeffrey Landers, Katarzyna Janczak, Jessica O'Konek
Journal: Journal of Allergy and Clinical Immunology (2022)

While aluminum adjuvant-based vaccines are commonly administered to neonates, their immune effects specific to early life are not well understood. The immature infant immune system is Th2-biased and dependent on environmental cues to mature towards Th1/Th2 balance. Thus, the induction of strong Th2 immunity with alum vaccines in early life may perturb this balance, leading to predisposition towards development of Th2 immunity to subsequent allergen exposure.
World AIDS Day — December 1, 2019
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

World AIDS Day, observed annually on December 1, draws attention to the status of the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic. Approximately 37.9 million persons worldwide are living with HIV infection, including 1.7 million persons newly infected in 2018 (1).
Salvage of Heparinized Blood with Acid-Citrate-Dextrose
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Negative Media Coverage as a Barrier to Accessing Care for Transgender Children and Adolescents
Authors: Ken C. Pang, Monsurul Hoq, Thomas D. Steensma
Journal: JAMA Network Open (2022)

Malin Indremo, MS; Anna Clara Jodensvi, MD; Hans Arinell, BSc; Johan Isaksson, PhD; Fotios C. Papadopoulos, PhD
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes
Authors: Evangelos K. Oikonomou, Marc A. Suchard, Darren K. McGuire, Rohan Khera
Journal: Diabetes Care (2022)

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented cardioprotective effects but are underused, partly because of high cost. We aimed to develop a machine learning-based decision support tool to individualize the atherosclerotic cardiovascular disease (ASCVD) benefit of canagliflozin in type 2 diabetes.
Dexamethasone in Hospitalized Patients with Covid-19
Authors: Peter Horby, Wei Shen Lim, Jonathan R Emberson, Marion Mafham, Jennifer L Bell, Louise Linsell, Natalie Staplin, Christopher Brightling, Andrew Ustianowski, Einas Elmahi, Benjamin Prudon, Christopher Green, Timothy Felton, David Chadwick, Kanchan Rege, Christopher Fegan, Lucy C Chappell, Saul N Faust, Thomas Jaki, Katie Jeffery, Alan Montgomery, Kathryn Rowan, Edmund Juszczak, J Kenneth Baillie, Richard Haynes, Martin J Landray
Journal: New England Journal of Medicine (2020)

BackgroundCoronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.MethodsIn this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment.ResultsA total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55).ConclusionsIn patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.) Quick Take Dexamethasone and Covid-19 2m 20s